Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spire Healthcare GroupCHIX:SPIL +0.93%75 Debt-to-EBITDA is 5.45 as of Dec. 2025, which is 7% below its 10-year median of 5.88. GuruFocus rates CHIX:SPIL with a GF Score™ of 75/100 and a GF Value™ of £2.71 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 478 Healthcare Providers & Services companies, Spire Healthcare Group ranks worse than 77.62% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Spire Healthcare Group's Debt-to-EBITDA or its related term are showing as below:
CHIX:SPIl'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -22.55 Med: 5.88 Max: 11.31
Current: 5.44
During the past 13 years, the highest Debt-to-EBITDA Ratio of Spire Healthcare Group was 11.31. The lowest was -22.55. And the median was 5.88.
CHIX:SPIl's Debt-to-EBITDA is ranked worse than 77.62% of 478
companies
in the Healthcare Providers & Services industry
Industry Median: 2.25
vs CHIX:SPIl: 5.44
Spire Healthcare Group (CHIX:SPIl) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Spire Healthcare Group Debt-to-EBITDA Related Terms
Spire Healthcare Group Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Spire Healthcare Group's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:SPIL vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Spire Healthcare Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spire Healthcare Group Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Spire Healthcare Group's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Spire Healthcare Group's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Spire Healthcare Group (CHIX:SPIL) has a Debt-to-EBITDA of 5.45 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Spire Healthcare Group. This is near median its historical median of 5.88. According to the industry distribution chart, Spire Healthcare Group ranks #371 out of 478 companies in the Healthcare Providers & Services industry, placing it in the top 77.6%.
Is Spire Healthcare Group's Debt-to-EBITDA too high?
Spire Healthcare Group's current Debt-to-EBITDA of 5.45 is near median its 10-year median of 5.88. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.25. Spire Healthcare Group's value of 5.45 is 142.2% above this industry median. Based on the distribution chart, Spire Healthcare Group ranks #371 out of 478 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Spire Healthcare Group has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Spire Healthcare Group's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Spire Healthcare Group ranks #371 out of 478 companies for Debt-to-EBITDA. This places Spire Healthcare Group in the lower half of its industry. The industry median Debt-to-EBITDA is 2.25. Spire Healthcare Group's value of 5.45 is 142.2% above this benchmark. While the company's 10-year median is 5.88 vs. the industry median of 2.25, Spire Healthcare Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.25, based on 478 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spire Healthcare Group's current Debt-to-EBITDA of 5.45 is 142.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Spire Healthcare Group. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spire Healthcare Group's current Debt-to-EBITDA is 5.45, which is near median its own 10-year median of 5.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spire Healthcare Group stock overvalued right now?
Based on GuruFocus' analysis, Spire Healthcare Group (CHIX:SPIL) is currently considered Modestly Undervalued. The stock's GF Value™ is £2.71, compared to a current price of £2.18 — trading 19.6% below its estimated fair value. The current Debt-to-EBITDA is 5.45, which is near median its 10-year median of 5.88 and 142.2% above the Healthcare Providers & Services industry median of 2.25. Spire Healthcare Group's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Spire Healthcare Group (CHIX:SPIL), the current Debt-to-EBITDA is 5.45 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spire Healthcare Group (CHIX:SPIL) Overvalued in 2026?
Based on GuruFocus' analysis, Spire Healthcare Group stock appears to be undervalued.
The current stock price of £2.18 is trading 19.6% below its estimated GF Value™ of £2.71.
GuruFocus considers Spire Healthcare Group to be Modestly Undervalued.
Key valuation signals for CHIX:SPIL:
Debt-to-EBITDA: 5.45 (near median its 10-year median of 5.88)
GF Value™: £2.71 vs. price of £2.18 (19.6% below fair value)
Industry Position: 142.2% above the Healthcare Providers & Services median (#371 of 478)
No single metric tells the full story. See the CHIX:SPIL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spire Healthcare Group PLC is an independent hospital group in the United Kingdom. It is a private provider, by volume, of knee and hip operations in the United Kingdom. The company has two operating segments: the hospitals business and the Primary care. The company generates the majority of its revenue from Hospital Business, which consists of hospitals, clinics, medical centres and consulting rooms. The company provide diagnostics, inpatient, day case and outpatient care in areas including orthopaedics, gynaecology, cardiology, neurology, oncology and general surgery. The primary care segment encompasses services focused on the primary care needs of outpatients, including GP services, occupational health services or mental and physical health services.
75GF Score
Get the complete analysis for CHIX:SPIL
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:SPIL has been successfully added to your 
